2. Search Result
Search Result
Results for "

kinase selectivity

" in MedChemExpress (MCE) Product Catalog:

986

Inhibitors & Agonists

4

Screening Libraries

3

Fluorescent Dye

2

Biochemical Assay Reagents

23

Peptides

18

Natural
Products

23

Isotope-Labeled Compounds

10

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137813
    PERK-IN-4

    		PERK Neurological Disease Metabolic Disease Cancer
    PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states .
    PERK-IN-4
  • HY-131335
    p38α inhibitor 2

    		p38 MAPK Inflammation/Immunology
    p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC50=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .
    p38α inhibitor 2
  • HY-148907
    CS640

    		CaMK MEK Mixed Lineage Kinase Cancer
    CS640 is a selective inhibitor of calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC50 values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC50 values of 6 and 10 μM, respectively .
    CS640
  • HY-132293
    BAY-8400
    2 Publications Verification

    		 DNA-PK Cancer
    BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer .
    BAY-8400
  • HY-D2415
    BODIPY-FL staurosporine

    		Fluorescent Dye Others
    BODIPY-FL staurosporine (Compound 8a) is a fluorescence probe based on staurosporine, exhibiting high specificity towards tyrosine kinases (TK) and tyrosine kinase-like (TKL) family kinases. BODIPY-FL staurosporine has the potential to develop binding assays for kinases that are not recommended for use with Kinase Tracer 236, such as PIM3, CDC42BPG, MAP2K7, TXK, and SIK3. BODIPY-FL staurosporine can be a powerful tool for analyzing kinase selectivity in kinase drug discovery .
    BODIPY-FL staurosporine
  • HY-161179
    TRK-IN-27

    		Trk Receptor Cancer
    TRK-IN-27 (Compound 14q) is a potent TRK inhibitor with good kinase selectivity. TRK-IN-27 effectively inhibits tumor growth .
    TRK-IN-27
  • HY-133850
    10-DEBC

    		Pim Cancer
    10-DEBC is a selective Akt inhibitor. 10-DEBC shows strong inhibitory activity against Moloney murine leukemia virus (Pim) kinase-1 (IC50=1.28 μM) .
    10-DEBC
  • HY-147784
    HZ-A-005

    		Btk Cancer
    HZ-A-005 is a potent, selective, and covalent Bruton’s tyrosine kinase (BTK) inhibitor. HZ-A-005 markedly decreases tumor growth in xenograft mouse models .
    HZ-A-005
  • HY-158154
    EGFR-IN-110

    		EGFR Cancer
    EGFR-IN-110 (Compound 6) is a covalent EGFR inhibitor, with pIC50 values of 9.2 and 8.7 for EGFR enzyme and EGFR cell, respectively. EGFR-IN-110 shows high EGFR potency and good kinase selectivity .
    EGFR-IN-110
  • HY-147695
    c-Met-IN-12

    		c-Met/HGFR Cancer
    c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .
    c-Met-IN-12
  • HY-121037
    Eggmanone

    EGM1

    		 Phosphodiesterase (PDE) Cancer
    Eggmanone (EGM1) is a potent and selective phosphodiesterase 4 (PDE4) antagonist with an IC50 of 72 nM for PDE4D3. Eggmanone shows approximately 40- to 50-fold selective for PDE4D3 over other PDEs. Eggmanone exerts its Hh-inhibitory effects through selective antagonism of PDE4, leading to protein kinase A activation and subsequent Hh blockade .
    Eggmanone
  • HY-109143
    Elsubrutinib

    ABBV-105

    		 Btk Inflammation/Immunology
    Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease .
    Elsubrutinib
  • HY-150752
    BTK-IN-15

    		Btk Pyroptosis Cancer
    BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .
    BTK-IN-15
  • HY-163476
    PIP5K1C-IN-1

    		Others Inflammation/Immunology Cancer
    PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor, with an IC50 of 0.80 nM. PIP5K1C-IN-1 exhibits low total clearance in mice and high levels of kinase selectivity. PIP5K1C-IN-1 can be used for the research of cancer and chronic pain .
    PIP5K1C-IN-1
  • HY-126323
    TCMDC-135051

    		Parasite Infection
    TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051
  • HY-126323B
    TCMDC-135051 hydrochloride

    		Parasite Infection
    TCMDC-135051 hydrochloride is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 hydrochloride prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 hydrochloride has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051 hydrochloride
  • HY-126323A
    TCMDC-135051 TFA

    		Parasite Infection
    TCMDC-135051 TFA is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 TFA prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 TFA has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051 TFA
  • HY-148794
    Risvodetinib

    IkT-148009

    		 c-Met/HGFR Bcr-Abl Neurological Disease Cancer
    Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .
    Risvodetinib
  • HY-46531
    Thalidomide-5-NH2-CH2-COOH

    		Ligands for E3 Ligase Inflammation/Immunology Cancer
    Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1) .
    Thalidomide-5-NH2-CH2-COOH
  • HY-117393
    Bisindolylmaleimide III

    		PKC Cancer
    Bisindolylmaleimide III is a potent and selective inhibitor of protein kinase C (PKC). Bisindolylmaleimide III selectively interacts with either PKCα or ribosomal S6 protein kinase 1 after activation of these kinases .
    Bisindolylmaleimide III
  • HY-144991
    Aurora kinase inhibitor-8

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-8 is a highly selective inhibitor of the Aurora kinases.
    Aurora kinase inhibitor-8
  • HY-152155
    ARUK2001607

    		PI5P4K Inflammation/Immunology Cancer
    ARUK2001607 is a selective phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) inhibitor with a Kd of 7.1 nM. ARUK2001607 shows high selectivity over other >150 kinases .
    ARUK2001607
  • HY-15979
    H-89
    115+ Cited Publications

    		 PKA Autophagy Neurological Disease
    H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
    H-89
  • HY-131065
    MET kinase-IN-2

    		c-Met/HGFR Cancer
    MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity .
    MET kinase-IN-2
  • HY-P3921
    Casein Kinase II Substrate

    		Casein Kinase Cancer
    Casein Kinase II Substrate is a casein kinase II (CK2) peptide substrate that can be selectively phosphorylated by CK2 .
    Casein Kinase II Substrate
  • HY-162785
    XC219

    		CDK Infection
    XC219 (compound 43) is a cyclin-dependent kinase CDK) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research .
    XC219
  • HY-110052
    TBCA

    		Casein Kinase Cancer
    TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
    TBCA
  • HY-13820
    GSK2656157
    45+ Cited Publications

    		 PERK Autophagy Apoptosis Cancer
    GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
    GSK2656157
  • HY-15979A
    H-89 dihydrochloride
    115+ Cited Publications

    		 PKA Autophagy Others
    H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.
    H-89 dihydrochloride
  • HY-117658
    GSK-114

    		Others Cardiovascular Disease
    GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 µM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .
    GSK-114
  • HY-16966
    SBI-0206965
    20+ Cited Publications

    		 ULK Autophagy Apoptosis Cancer
    SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2 .
    SBI-0206965
  • HY-100556
    Tie2 kinase inhibitor 1
    1 Publications Verification

    		 Tie Cancer
    Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM . Tie2 kinase inhibitor 1 has anti-cancer activity .
    Tie2 kinase inhibitor 1
  • HY-19362
    AZD3264
    2 Publications Verification

    		 IKK Inflammation/Immunology
    AZD3264 is a selective IkB-kinase IKK2 inhibitor.
    AZD3264
  • HY-153436
    RIP1 kinase inhibitor 6

    		RIP kinase Cancer
    RIP1 kinase inhibitor 6 is a potent and selective RIP1 kinase inhibitor with an IC50 of < 100 nM in human R1P1 kinase assay. RIP1 kinase inhibitor 6 is extracted from patent WO2020103884, example 80 .
    RIP1 kinase inhibitor 6
  • HY-118151
    Rho-Kinase-IN-3

    		ROCK Cardiovascular Disease Neurological Disease
    Rho-Kinase-IN-3 (compound 12) is a potent and selective Rho kinase (ROCK1) inhibitor with an IC50 value of 8 nM. Rho-Kinase-IN-3 can be used in research of hypertension .
    Rho-Kinase-IN-3
  • HY-112907
    RIP2 Kinase Inhibitor 3

    		RIP kinase Inflammation/Immunology
    RIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of receptor interacting protein-2 (RIP2) Kinase with an IC50 of 1 nM .
    RIP2 Kinase Inhibitor 3
  • HY-50686
    Tivantinib
    10+ Cited Publications

    ARQ 197; (3R,4R)-ARQ 198

    		 c-Met/HGFR Apoptosis Cancer
    Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.
    Tivantinib
  • HY-59047
    Tolimidone
    3 Publications Verification

    MLR-1023

    		 Src Metabolic Disease
    Tolimidone is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.
    Tolimidone
  • HY-P1561
    PKG Substrate

    		PKG Neurological Disease
    PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).
    PKG Substrate
  • HY-10578
    PD 169316
    10+ Cited Publications

    		 p38 MAPK Autophagy Enterovirus Cancer
    PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71.
    PD 169316
  • HY-12470A
    PF-4800567 hydrochloride

    		Casein Kinase Cancer
    PF-4800567 hydrochloride is a potent and selective inhibitor of?casein kinase?1? (CK1?), with an?IC50?of 32 nM, which is greater than 20-fold selectivity over CK1δ (IC50, 711 nM). PF-4800567 hydrochloride is useful in probing unique roles between these two kinases in multiple signaling pathways .
    PF-4800567 hydrochloride
  • HY-157995
    Dyrk1A-IN-7

    		DYRK Metabolic Disease Inflammation/Immunology Cancer
    Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .
    Dyrk1A-IN-7
  • HY-111941
    GSK8612
    10+ Cited Publications

    		 IKK Neurological Disease Inflammation/Immunology Cancer
    GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1 .
    GSK8612
  • HY-112355
    Aurora kinase inhibitor-2

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .
    Aurora kinase inhibitor-2
  • HY-19353
    SR7826
    1 Publications Verification

    		 LIM Kinase (LIMK) Neurological Disease Cancer
    SR7826 is a class of bis-aryl urea derived potent, selective and orally active LIM kinase (LIMK) inhibitor with an IC50 of 43 nM for LIMK1. SR7826 is >100-fold more selective for LIMK1 than ROCK and JNK kinases .
    SR7826
  • HY-15604
    AZD1208
    10+ Cited Publications

    		 Pim Autophagy Apoptosis Cancer
    AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor .
    AZD1208
  • HY-15604A
    AZD1208 hydrochloride

    		Pim Autophagy Apoptosis Cancer
    AZD1208 hydrochloride is an orally bioavailable, highly selective PIM kinases inhibitor .
    AZD1208 hydrochloride
  • HY-144706
    Axl-IN-3

    		TAM Receptor Cancer
    Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC50 of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .
    Axl-IN-3
  • HY-15728
    Radotinib

    IY-5511

    		 Bcr-Abl Cancer
    Radotinib(IY-5511) is a novel and selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM for wild-type BCR-ABL1 kinase.
    Radotinib
  • HY-152107
    LRRK2-IN-7

    		LRRK2 Neurological Disease
    LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .
    LRRK2-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: